ライフサイエンスコーパス: hearing loss

1 earing health behaviors in older adults with hearing loss.

2 ural TFS for older listeners without or with hearing loss.

3 correlation between smoking and age-related hearing loss.

4 003), but blood lead was not associated with hearing loss.

5 naive cells towards otic identity to restore hearing loss.

6 ter hair cells, despite concomitant profound hearing loss.

7 on (COME) is the leading cause of conductive hearing loss.

8 ease, and a major determinant of age-related hearing loss.

9 in gap detection induced by early transient hearing loss.

10 ctant working against aminoglycoside-induced hearing loss.

11 ith perceptual challenges arising from early hearing loss.

12 iles ranging from normal hearing to moderate hearing loss.

13 ay be an important modifiable contributor to hearing loss.

14 ciation between ZIKV infection and transient hearing loss.

15 igmentation were not associated with risk of hearing loss.

16 ney damage, balance disorders, and permanent hearing loss.

17 linicians to consider the broader impacts of hearing loss.

18 effects on coexpressed connexins cause only hearing loss.

19 identify 52 new candidate genes for genetic hearing loss.

20 n adolescents may play a role in the risk of hearing loss.

21 eived but restricted to those assessable for hearing loss.

22 treatments for older adults with age-related hearing loss.

23 e from performing tasks in older adults with hearing loss.

24 communication partner-reported complaints of hearing loss.

25 -inactive MEKK4 mutation exhibit significant hearing loss.

26 ll pathologies in the cochlea and functional hearing loss.

27 zation of a novel mouse model of age-related hearing loss.

28 to approximately 60% of cases of congenital hearing loss.

29 is a common disorder that often complicates hearing loss.

30 dation, vision impairment, and sensorineural hearing loss.

31 erious side effects, including sensorineural hearing loss.

32 ich is an established cause of sensorineural hearing loss.

33 sting involvement of S1P signalling in human hearing loss.

34 mulation in the terminal may protect against hearing loss.

35 A 6-year-old girl presented with bilateral hearing loss.

36 for approximately 20% of cases of hereditary hearing loss.

37 has lower limb malformations in addition to hearing loss.

38 ditory brainstem during and after conductive hearing loss.

39 characterised by severe vertigo attacks and hearing loss.

40 exhibit a significant reduction of HCs and a hearing loss.

41 congenital anomalies, neoplasm, or vision or hearing loss.

42 its mutation may contribute to sensorineural hearing loss.

43 NF2 and confirmed progressive VS-associated hearing loss.

44 tein function can lead to RP with or without hearing loss.

45 afness-causing allele to slow progression of hearing loss.

46 l infection, and leading cause of conductive hearing loss.

47 ion can influence the progression of genetic hearing loss.

48 munication difficulties faced by people with hearing loss.

49 edial footplate and an associated conductive hearing loss.

50 S and ENV following permanent, noise-induced hearing loss.

51 anscriptase PCR, or (iii) new vision loss or hearing loss.

52 use stereociliary bundle disorganization and hearing loss.

53 and it typically presents with sensorineural hearing loss.

54 ochlear hair cell degeneration, and profound hearing loss.

55 s alone or in skin pathologies with comorbid hearing loss.

56 cs has been associated with a higher risk of hearing loss.

57 s pigmentosa (RP) and bilateral neurosensory hearing loss.

58 th/+) mice substantially reduced progressive hearing loss.

59 ns to cochlear hair cells, causing permanent hearing loss.

60 reatment of some types of autosomal-dominant hearing loss.

61 role of GPx1 activity in acute noise-induced hearing loss.

62 0.001) were associated with higher risks of hearing loss.

63 llion people worldwide suffer from disabling hearing loss.

64 ion may form the basis for otoferlin-related hearing loss.

65 essment and to evaluate existing measures of hearing loss.

66 eurodegeneration and exacerbates age-related hearing loss.

67 on for both the children and the adults with hearing loss.

68 it a simple differential diagnosis of hidden hearing loss.

69 ead to many skin disorders and sensorineural hearing loss.

70 e central auditory system during age-related hearing loss.

71 The primary endpoint was incidence of hearing loss 4 weeks after final cisplatin dose.

72 Seventy-nine percent suffered hearing loss, 58% never learned to speak, and nearly all

73 ximately half a billion people had disabling hearing loss, about 6.8% of the world's population.

74 , with stapes malformations correlating with hearing loss across all frequencies.

75 in outer hair cells, leads to a progressive hearing loss after 1 month, suggesting that Ocm critical

76 V) in Brazil, we identified 3 cases of acute hearing loss after exanthematous illness.

77 nbred mouse strains, accelerates age-related hearing loss (AHL) and can worsen auditory phenotypes of

78 rstood how distinct GJB2 mutations result in hearing loss alone or in skin pathologies with comorbid

79 The sibling with hearing loss also harbored a homozygous mutation in GJB2

80 duration of analgesic use and self-reported hearing loss among 55,850 women in the Nurses' Health St

81 Mid-frequency to high-frequency hearing loss, an expected adverse event, was documented

82 etion or duplication syndromes often display hearing loss and behavioral disorders, including ADHD an

83 (HCMV) is the most common cause of childhood hearing loss and can lead to neurodevelopmental delay.

84 C, respectively, modulates cisplatin-induced hearing loss and cell death in the organ of Corti, the a

85 Ageing is associated with hearing loss and changes in GABAergic signalling in the

86 ient mice that are models DFNB1 nonsyndromic hearing loss and deafness.

87 detection and intervention for sensorineural hearing loss and developmental delay, where appropriate.

88 iral therapy for affected newborns to reduce hearing loss and from earlier identification of hearing

89 2013, and point to the growing importance of hearing loss and global hearing health care.

90 imulation; and could attenuate noise-induced hearing loss and hair cell damage.

91 2), there was no association between risk of hearing loss and hair color (for black hair vs. red or b

92 deficiencies predispose to cisplatin-induced hearing loss and hair/supporting cell damage in the mamm

93 s identify treatments that could prevent the hearing loss and hearing disorders that result from nois

94 t prevalent form of hearing loss, conductive hearing loss and its effects on central synapses have re

95 loss disorders, such as sudden sensorineural hearing loss and Meniere's disease that are elicited by

96 In this Review, we describe the burden of hearing loss and offer our and others' recommendations f

97 r cells, but not in neurons, causes profound hearing loss and outer hair cell degeneration in mice.

98 nce of Np65 causes early-onset sensorineural hearing loss and prevented the normal synaptogenesis in

99 nce of Np65 causes early-onset sensorineural hearing loss and prevents normal neurotransmitter releas

100 for immune response, leukaemia, age-related hearing loss and rheumatoid arthritis.

101 air, are hypersensitive to cisplatin-induced hearing loss and sensory hair cell death in the organ of

102 gated the relationship between self-reported hearing loss and skin pigmentation by using hair color,

103 ew insights into mechanisms of noise-induced hearing loss and suggests novel interventions for the pr

104 in ACTG1 was found to be co-segregated with hearing loss and the genetic cause of ADNSHI in this fam

105 nts from the perspectives of the person with hearing loss and their communication partner.

106 Glucocorticoids have been used to treat hearing loss and vestibular dysfunction for many years.

107 iovascular disease, fatty liver, age-related hearing loss, and breast cancer.

108 ange of disorders characterized by seizures, hearing loss, and neurodegeneration.

109 two unrelated individuals with microcephaly, hearing loss, and overlapping dysmorphic features.

110 nfection, identifying 1 case of cCMV-related hearing loss, and preventing 1 cochlear implant; the inc

111 to form domains representing the person with hearing loss- and communication partner-reported complai

112 ms to synthesize the evidence on person with hearing loss- and communication partner-reported complai

113 tal reduction in cases of severe to profound hearing loss; and the differences in costs per infant sc

114 od degeneration accompanied by sensorineural hearing loss (arCRD-SNHL).

115 Age-related hearing loss (ARHL) is associated with changes to the au

116 ABSTRACT: Age-related hearing loss (ARHL) is associated with changes to the au

117 Here, we show that mild hearing loss as a result of brief noise exposure leads t

118 apeutic agent, yet it often causes permanent hearing loss as a result of sensory hair cell death.

119 Cre) mice exhibit an early onset progressive hearing loss as compared with their wild-type littermate

120 communication partner-reported complaints of hearing loss as reported in research.

121 w-cost possibilities exist for prevention of hearing loss, as do unprecedented opportunities to reduc

122 The item content of hearing loss assessment tools should seek to capture the

123 background and congenic regions have on the hearing loss associated with Cdh23(c.753)alleles.

124 AC1 mice displayed delayed onset progressive hearing loss associated with deterioration of the hair b

125 ption of this mechanism is the root cause of hearing loss associated with EES.

126 Mutations of SLC26A4 are a common cause of hearing loss associated with enlargement of the endolymp

127 The severity of long-term hearing loss at 3 weeks after infection, measured by aud

128 The cumulative incidence of grade 3-4 hearing loss at 3 years was 12% (95% CI 4-25).

129 to 800 mg/m(2)) was significantly related to hearing loss at 4, 6, 8, 10, and 12 kHz (P trends, .021

130 eptor developmentally resulted in a profound hearing loss at young adult stages.

131 ic intracranial hemorrhage, of whom none had hearing loss, ataxia, or myelopathy.

132 ntracranial hemorrhage, of whom 39 (83%) had hearing loss, ataxia, or myelopathy; type 2 (secondary)

133 This synaptopathy has been termed hidden hearing loss because its effects are not thought to be r

134 d and revealed moderate to severe conductive hearing loss bilaterally, with a mixed component present

135 ere associated with slightly higher risks of hearing loss, but duration of aspirin use was not.

136 ing inflammatory and apoptotic processes and hearing loss by activating signal transducer and activat

137 n of sound in people with severe-to-profound hearing loss by electrically stimulating the cochlear ne

138 nically relevant conditions of sensorineural hearing loss by examining the role of fractalkine signal

139 y dependent and contributes to noise-induced hearing loss by mediating the loss of inner hair cell sy

140 ion have shown that adaptation to asymmetric hearing loss can be achieved either by reinterpreting al

141 consequences: even relatively mild levels of hearing loss can lead to cascading cognitive effects tha

142 In childhood, partial hearing loss can produce prolonged deficits in speech pe

143 hile the peripheral effects of sensorineural hearing loss certainly contribute to this difficulty, di

144 ecreased activity can result from conductive hearing loss (CHL) associated with otitis media, which m

145 lored the effect of developmental conductive hearing loss (CHL) in gerbils on MMR characteristics, as

146 to date no one has synthesized the range of hearing loss complaints from the perspectives of the per

147 more than 400 human genetic syndromes with a hearing loss component.

148 pite being the second most prevalent form of hearing loss, conductive hearing loss and its effects on

149 Genetic factors play an important role in hearing loss, contributing to approximately 60% of cases

150 Temporary hearing loss could cause similar changes at later stages

151 ias because participants with high frequency hearing loss demonstrated shorter response latencies whe

152 tem (GMFCS) level of 3 to 5, or blindness or hearing loss despite amplification.

153 significant and understudied cause of human hearing loss, diagnosed in patients who demonstrate abno

154 ociated with age and cortical thickness, but hearing loss did not independently contribute to the cha

155 Where assessed, degree of unaided hearing loss did not play a major moderating role.

156 A34, CAPS, and possibly in a wide variety of hearing-loss disorders, such as sudden sensorineural hea

157 Accelerated age-related hearing loss disrupts high-frequency hearing in inbred C

158 esium (ACEMg) can be beneficial for reducing hearing loss due to aminoglycosides and overstimulation.

159 o potential therapeutic targets for treating hearing loss due to perturbation of any component of the

160 and suggests that therapies for humans with hearing loss due to S1P signalling defects need to targe

161 Cochlear synaptopathy (or hidden hearing loss), due to noise exposure or aging, has been

162 cingulate cortex) correlated positively with hearing loss duration.

163 In apical fibers, more classical hearing-loss effects were observed, i.e., broadened tuni

164 The M163V mutant, which causes only hearing loss, exhibited impaired gap junction function a

165 f a novel disorder of platelet formation and hearing loss extends the repertoire of DIAPH1-related di

166 to identify the genetic cause in hereditary hearing loss families.

167 y and how this could relate to sensorineural hearing loss following peripheral impairment.SIGNIFICANC

168 ed in a viral vector can slow progression of hearing loss for up to 35 weeks in the Beethoven mouse,

169 ation of aspirin use was not associated with hearing loss (for >6 years of use compared with <1 year,

170 Its use results in significant and permanent hearing loss, for which no US Food and Drug Administrati

171 ing aids for children with mild and moderate hearing losses, for which the median age fell from 19 to

172 Over 100 non-syndromic hearing loss genes have been identified in mouse and hum

173 We detect known hearing loss genes, but the vast majority, 52, of the ca

174 In total, we identify 67 candidate hearing loss genes.

175 Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, eff

176 However, the specific defects that lead to hearing loss have not been described.

177 Hidden hearing loss (HHL) is a recently described auditory neur

178 Cortical thickness, but not hearing loss, improved the prediction of all imaging var

179 of the Cdh23(c.753A) allele, which worsened hearing loss in 129S1 mice.

180 Cisplatin chemotherapy causes permanent hearing loss in 40-80% of treated patients.

181 o-acts with a dominant mutation to result in hearing loss in a dominant family.

182 ted the association between heavy metals and hearing loss in a general population that includes adult

183 y of Cas9-guide RNA complexes can ameliorate hearing loss in a mouse model of human genetic deafness.

184 o lead, mercury, and cadmium and the risk of hearing loss in adults and adolescents while controlling

185 753G) allele, which prevented high frequency hearing loss in B6 mice to at least 18 months of age, an

186 osulfate for prevention of cisplatin-induced hearing loss in children and adolescents.

187 iosulfate protects against cisplatin-induced hearing loss in children and is not associated with seri

188 iosulfate protects against cisplatin-induced hearing loss in children and is not associated with seri

189 effusion (COME) is the most common cause of hearing loss in children, and known to have high heritab

190 thway could underlie treatable sensorineural hearing loss in DFNA34, CAPS, and possibly in a wide var

191 y processing deficits.SIGNIFICANCE STATEMENT Hearing loss in early childhood leads to impairments in

192 accharide (LPS)-induced sudden sensorineural hearing loss in guinea pigs.

193 tant mouse model (Beethoven) for progressive hearing loss in humans (DFNA36), which harbors a point m

194 n that most autosomal-dominant non-syndromic hearing loss in humans is caused by this mechanism of ac

195 -muscle Myosin II, a protein associated with hearing loss in humans.

196 Early onset profound hearing loss in KO mice and lack of information about th

197 ntaining HDAC2 expression levels, preventing hearing loss in LPS-exposed animals and reducing cochlea

198 terozygous mice did not examine or report on hearing loss in mature animals, it has not been clinical

199 e been linked to syndromic and non-syndromic hearing loss in mice and humans.

200 ve been linked to syndromic and nonsyndromic hearing loss in mice and humans.

201 a diversity of conductive and sensorineural hearing loss in nearly half of AGS patients, many of whi

202 We observe similar stapes defects and hearing loss in one patient with heterozygous JAGGED1 lo

203 tackle the increasingly important problem of hearing loss in our aging population.

204 e both temporary and permanent noise-induced hearing loss in preclinical studies.

205 applicable to the detection of noise-induced hearing loss in stranded cetaceans.

206 signaling in the inner ear leads to profound hearing loss in the mouse.

207 LRP3 causes autosomal-dominant sensorineural hearing loss in two unrelated families.

208 ebselen for the prevention of noise-induced hearing loss in young adults in a phase 2 clinical trial

209 tive benefit, for people with high-frequency hearing loss, including people with dead regions (DRs) i

210 Sound deprivation by conductive hearing loss increases hearing thresholds, but little is

211 The prevalence of hearing loss increases rapidly with aging.

212 early, normal and delayed eyelid opening on hearing loss-induced changes to membrane and inhibitory

213 Noise-induced hearing loss is a leading cause of occupational and recr

214 Hearing loss is a major public health concern with no ph

215 Hearing loss is a neurofunctional deficit occurring in u

216 the obstacles, a diagnostic test for hidden hearing loss is a worthwhile goal, with important implic

217 In family LMG446, hearing loss is accompanied by autoinflammatory signs an

218 The CP for recovery from hearing loss is also closed prematurely by early eyelid

219 Hearing loss is an important sequela of pneumococcal men

220 Hearing loss is common in all age groups, even in young

221 Progressive sensorineural hearing loss is observed in a subset of NER-associated D

222 en duration of analgesic use and the risk of hearing loss is unclear.

223 Progressive hearing loss is very common in the population but we sti

224 and that heterozygous mice actually develop hearing loss late in life.

225 Hearing loss leads to a host of cellular and synaptic ch

226 re, we show that 10 d of monaural conductive hearing loss leads to an increase in hearing thresholds,

227 At a neural level, chronic hearing loss leads to reduced activation in central audi

228 evelopmental delay, intellectual disability, hearing loss, macrocephaly, distinct facial dysmorphisms

229 to validate otoprotection in an in vivo rat hearing loss model.

230 Noise induced hearing loss (NIHL) is a disease that affects millions o

231 Noise-induced hearing loss (NIHL) is an important occupational disorde

232 cs of both syndromic (SHL) and non-syndromic hearing loss (NSHL) is characterized by a high degree of

233 is challenging, as the lesions that lead to hearing loss occur at the cellular level and inner ear c

234 are thought to cause auditory neuropathy and hearing loss of cochlear origin by affecting noise-induc

235 sorder, whereas all other PJVK alleles cause hearing loss of cochlear origin.

236 served for both the children and adults with hearing loss on all tasks with few exceptions.

237 t tools should seek to capture the impact of hearing loss on everyday life, but to date no one has sy

238 Here, we review the effects of hearing loss on neural systems supporting spoken languag

239 y presented before age 3 years and developed hearing loss or other neurological features including at

240 is a promising approach by which to prevent hearing loss or to restore hearing after loss has occurr

241 fection may cause serious diseases including hearing loss, orchitis, oophoritis, mastitis, and pancre

242 : 1.05, 2.05) odds ratios for high-frequency hearing loss (p-trend<0.001 and=0.007), respectively.

243 3.03 (95% CI: 1.44, 6.40) for high-frequency hearing loss (p-trend=0.003), but blood lead was not ass

244 1 children and 17 adults with mild to severe hearing loss participated.

245 story of progressive bilateral sensorineural hearing loss presented to a neuro-ophthalmology clinic w

246 e has intellectual disability, sensorineural hearing loss requiring bilateral cochlear implants, skel

247 henotyping Consortium, the authors perform a hearing loss screen in 3006 mouse knockout strains and i

248 Mouse Phenotyping Consortium, we undertook a hearing loss screen in a cohort of 3006 mouse knockout s

249 In family LMG113, hearing loss segregates without any other target-organ m

250 en adults with mild to severe high-frequency hearing loss (seven with extensive DRs, one with patchy

251 Speech-Language-Hearing Association-defined hearing loss severity (odds ratio, 1.59; P = .0066) and

252 In addition, greater hearing loss severity and stigma were predictors in wome

253 anguage-Hearing Association criteria defined hearing loss severity.

254 First and foremost, treating hearing loss should be investigated as a means of improv

255 gainst cochlear synaptopathy associated with hearing loss.SIGNIFICANCE STATEMENT A single incidence o

256 Atoh1 alleles should be considered in human hearing loss.SIGNIFICANCE STATEMENT The discovery that A

257 sequencing in individuals with sensorineural hearing loss (SNHL) and identified pathogenic mutations

258 aneous vertigo associated with sensorineural hearing loss (SNHL) and tinnitus.

259 Sensorineural hearing loss (SNHL) at birth was associated with a posit

260 Individuals with sensorineural hearing loss (SNHL) often experience more difficulty wit

261 n therapy (RT) are at risk for sensorineural hearing loss (SNHL).

262 ring-impaired listeners with a sensorineural hearing loss (SNHL).

263 ly similar: severe disability, microcephaly, hearing loss, spasticity, and characteristic brain imagi

264 Even mild hearing loss strongly affects this ability in humans, se

265 und noise.SIGNIFICANCE STATEMENT People with hearing loss struggle to follow conversations in noisy e

266 In acquired sensorineural hearing loss, such as that produced by noise or aging, t

267 recordings in ferrets reared with asymmetric hearing loss suggest that these forms of plasticity have

268 t association between CYP2A6 rs113288603 and hearing loss symptoms (p = 5.75 x 10(-5)).

269 Black individuals have a lower risk of hearing loss than do whites, possibly because of differe

270 Furthermore, when coupled with transient hearing loss that animals normally fully recover from, v

271 related pedigrees with MTP and sensorineural hearing loss that segregate with a DIAPH1 R1213* variant

272 old elevation, can nonetheless cause "hidden hearing loss" that interferes with coding of suprathresh

273 In patients with bilateral hearing loss, the use of two hearing aids (HAs) offers t

274 that causes significant morbidity, including hearing loss, tinnitus, dizziness, and possibly even dea

275 (G321S) that has been linked to progressive hearing loss to further examine the inhibitory effects o

276 Recent research has linked age-related hearing loss to impaired performance across cognitive do

277 ation of hearing impairment in 42 unilateral hearing loss (UHL) patients with acoustic neuromas compa

278 nfection as the key determinant of long-term hearing loss, underlining the importance of the prompt i

279 An ability to adapt to asymmetric hearing loss using multiple adaptive processes is theref

280 p6v1b1 mutant mice provides insight into the hearing loss variability associated with dRTA caused by

281 equency (3, 4, and 6 kHz) were computed, and hearing loss was defined as a PTA>25 dB in adults and PT

282 eading to recessive, early-onset progressive hearing loss was detected and exome sequencing revealed

283 In the absence of treatment, significant hearing loss was detected in LPS-exposed animals.

284 Hearing loss was identified in 14 (28.6%; 95% CI 16.6-43

285 At 2.5 years of age, a diagnosis of hearing loss was made, and she was given hearing aids.

286 stratification variables, the likelihood of hearing loss was significantly lower in the sodium thios

287 ficant association between blood mercury and hearing loss was suggested in either adults or adolescen

288 To determine how ESRP1 mutations cause hearing loss, we evaluated Esrp1(-/-) mouse embryos and

289 atypical association of LCA with early-onset hearing loss, we identified two heterozygous mutations a

290 e are currently no biological treatments for hearing loss, we sought to advance gene therapy approach

291 1-mutated patients of this latter group with hearing loss were diagnosed with autosomal dominant Wolf

292 Costs of laboratory testing, treatment, and hearing loss were drawn from Medicaid data and published

293 s, organ of Corti degeneration, and profound hearing loss were observed.

294 Children with profound hearing loss were referred for CI assessment at a signif

295 keratinocytes will lead to skin diseases and hearing loss, whereas mutants having reduced channel fun

296 treating GJB2 and other forms of hereditary hearing loss with ACEMg, we tested the influence of ACEM

297 , which encodes pendrin, are responsible for hearing loss with an enlarged vestibular aqueduct and Pe

298 ring loss and from earlier identification of hearing loss with postnatal onset.

299 dies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin w

300 ssment tools exist to evaluate the impact of hearing loss, with little consensus among researchers as